Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Neely

Showing results (41-50 of 96) with videos related to

Pageof 10
Sort By:
Antimicrobial Agents and Chemotherapy|December 22, 2017
Pharmacokinetic/Pharmacodynamic Determinants of Vancomycin Efficacy in Enterococcal BacteremiaMuhammed Taufiq Bin Jumah, Shawn Vasoo, Sanjay R Menon, et al.
Journal of Clinical Pharmacology|October 29, 2021
Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts' Discussion on Use, Strengths, and LimitationsSylvain Goutelle, Jean-Baptiste Woillard, Thierry Buclin, et al.
Plos One|July 9, 2014
Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosisGeorge L Drusano, Michael Neely, Michael Van Guilder, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 22, 2020
Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycinBrian V Lee, Gary Fong, Michael Bolaris, et al.
Neuroreport|July 9, 2014
Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humansMegan M Yardley, Michael Neely, Nhat Huynh, et al.
British Journal of Clinical Pharmacology|April 5, 2014
Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patientsJean-Baptiste Woillard, Vincent Lebreton, Michael Neely, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 1, 2021
'Cost-benefit analysis comparing trough, two-level AUC, and Bayesian AUC dosing for vancomycin': authors' replyBrian V Lee, Gary Fong, Michael Bolaris, et al.
Therapeutic Drug Monitoring|February 2, 2016
Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose SoftwareMichael Neely, Michael Philippe, Teresa Rushing, et al.
The Pediatric Infectious Disease Journal|July 14, 2021
VP Shunt With Recurrent Malfunction in Two Pediatric Patients: Is the Hydrocephalus Truly Idiopathic?Mimi R Precit, Cynthia Enriquez, Michael Neely, et al.
Journal of Clinical Medicine|July 27, 2022
Assessment of Antibiotic Pharmacokinetics, Molecular Biomarkers and Clinical Status in Critically Ill Adults Diagnosed with Community-Acquired Pneumonia and Receiving Intravenous Piperacillin/Tazobactam and Hydrocortisone over the First Five Days of Intensive Care: An Observational Study (STROBE Compliant)István Vincze, Rita Czermann, Zsuzsanna Nagy, et al.
Pageof 10

Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
Antimicrobial Agents and Chemotherapy|December 22, 2017
Pharmacokinetic/Pharmacodynamic Determinants of Vancomycin Efficacy in Enterococcal BacteremiaMuhammed Taufiq Bin Jumah, Shawn Vasoo, Sanjay R Menon, et al.
Journal of Clinical Pharmacology|October 29, 2021
Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts' Discussion on Use, Strengths, and LimitationsSylvain Goutelle, Jean-Baptiste Woillard, Thierry Buclin, et al.
Plos One|July 9, 2014
Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosisGeorge L Drusano, Michael Neely, Michael Van Guilder, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 22, 2020
Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycinBrian V Lee, Gary Fong, Michael Bolaris, et al.
Neuroreport|July 9, 2014
Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humansMegan M Yardley, Michael Neely, Nhat Huynh, et al.
British Journal of Clinical Pharmacology|April 5, 2014
Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patientsJean-Baptiste Woillard, Vincent Lebreton, Michael Neely, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 1, 2021
'Cost-benefit analysis comparing trough, two-level AUC, and Bayesian AUC dosing for vancomycin': authors' replyBrian V Lee, Gary Fong, Michael Bolaris, et al.
Therapeutic Drug Monitoring|February 2, 2016
Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose SoftwareMichael Neely, Michael Philippe, Teresa Rushing, et al.
The Pediatric Infectious Disease Journal|July 14, 2021
VP Shunt With Recurrent Malfunction in Two Pediatric Patients: Is the Hydrocephalus Truly Idiopathic?Mimi R Precit, Cynthia Enriquez, Michael Neely, et al.
Journal of Clinical Medicine|July 27, 2022
Assessment of Antibiotic Pharmacokinetics, Molecular Biomarkers and Clinical Status in Critically Ill Adults Diagnosed with Community-Acquired Pneumonia and Receiving Intravenous Piperacillin/Tazobactam and Hydrocortisone over the First Five Days of Intensive Care: An Observational Study (STROBE Compliant)István Vincze, Rita Czermann, Zsuzsanna Nagy, et al.
Pageof 10